GekkoWire is devoted to providing unbiased information to Main Street investors. All information used in company analysis is from publicly available sources.
A majority of the posts will be geared to Pharmaceutical companies, but from time to time other posts will profile industries outside of the Pharma world.
GekkoWire is written by Mr. G. Chambers who is currently employed as an Economist. Prior to this position, Mr. Chambers worked in the Health Care Industry as a researcher for a DC public affairs firm. Mr. Chambers is a Cum Laude graduate of The University of Maryland, College Park where he majored with departmental honors in Economics and Finance.
GekkoWire.com will not be liable for any loss or damage caused by a reader’s reliance on information obtained in any form from our web site. Readers are solely responsible for their own investment decisions.
The opinions and analysis are based on publicly available sources believed to be reliable and are written in good faith, but no representation or warranty, expressed or implied, is made as to their accuracy or completeness. All information contained in this web site should be independently verified with the companies mentioned. The author is not responsible for errors or omissions.
GekkoWire receives no compensation of any kind from any companies that may be mentioned on our web site nor does its employees hold any positions in the companies that in depth analysis is provided for. Any opinions expressed are Mr. Chambers’ and are subject to change without notice.
Twitter
Nice site, thanks for the great research!
great site keep up the awesome work
Just came across your wonderful site. The FDA / Drug calendar is especially helpful. Many thanks!
Excellent content, thank you!!!
This is really the best biotech blog I’ve ever seen. Great stuff! Thanks for doing the research you do.
I will not hesitate to recommend your site to anyone interested in drug company, very good and objective analysis, very well done.
Love the site
lets make some money and more direct guidence. Nice place, but not leads.
Your site has given me lots of great details .It is certainly of your great effort in research n analysis. Looking forward to see more info’ on GNBT . Tq
Very interesting site. I learned a lot.
Do you have an opinion on Pharmagap a small Canadian company. Todays info looks good.
Thanks. Would like to support you, but can’t find an ad to click using Firefox 3.5.4. I’ll check again. Any opinion on the recent CTIC filings?
This site has become my favorite… easy to read..!!
Hi,
I have been regularly visiting this site and it is really helpful. Specially “my drug analysis article”. I would like to know your thoughts on PWRM, BIEL and LLBO if you can spare sometime.
Thanks in advance,
Josh
Great source of information.
I am a regular visitor.
Great site.
Just curious…
do you have any medical background ?
Appreciate the reply.
Keep up the excellent work. Your articles are insightful, well written, and the site deserves a lot more traffic. A request for some analysis or info’ on the following tickers would be great…
CXM, PPHM, ASTM, ICGN. Thanks!
Exelent work..!!! Congratulations..!!! Thou I Wuold like heard you wraiting about stem cell, new tecnology….ACTC , ASTM , GERN and many others..!!! Thanks
in advance…!!
Hello, your website is great and I enjoy reading all of your articles. They have a lot of information. I was wondering if we can get your opinion on AVXT. They have a phase III coming out in Jan.
Hello, I can’t find your email, so i write here.Apologize me.
You know something about Peregrine Pharamaceutic pphm?
Thank you so much
I will take a look soon.
Hello I have a question to ask.
I saw this article http://source.minyanville.com/businessmarkets/articles/5/11/2004/id/4441
and I noticed on point (2) that the accelerated apporval and designation as an orphan drug, have higher requirements than the spa.
Pixantrone is orphan in Europe but not in America, but in November, cell requested the accellerated approval. When we can know something about it.
I think accellerated approval it is a very important point to be evaluated.
Sorry for my english.
I answer by myself
5. Issues for Odac
• The randomized study was stopped at less than 50% of its planned accrual Because
of poor accrual. Do the data support efficacy for accelerated approval of pixantrone
The proposed indication?
So the Odac essentially must decide whether to give the accelerated approval.
In your opinion how many chances do we have?
I give the entire ODAC panel meeting a 50/50 chance. I think the vote might be a bit closer than usual given the nature of the patients. Either way it will be interesting to see what the ODAC thinks.
you should do a write up on GTHP
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20100223005229&newsLang=en
I will try to get to one as soon as possible, I am well aware that they have some very important milestones coming up.
I find this on forum
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM205356.pdf
what do you think?
Just came across this site in the last week here. It looks pretty good. One thing I don’t like is how the articles are split up into multiple pages…this makes it a hassle for save the articles to their Ipod Touches to read later (ie. using an app like Ipod Off or Instapaper). Could you think about removing the multiple pages?
Patrick,
I will not be removing the multiple pages, it is how the site generates revenue so it will stay that way. I don’t know much about the Ipod, but from what I understand it has a regular web browser, correct? I would just view it from there.
As for the copy and paste issue, you are free to try and copy and paste the article if you wish directly from the site, although I think you will find it more difficult than you think.
admin: oh OK. That’s cool. You gotta make your money!
The only issue with browsing in the Ipod Touch is that the page number buttons are fairly small. Makes them hard to hit. But it’s really not a big deal.